Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer.
about
When prostate cancer remains undetectable: The dilemmaTransperineal prostate biopsy: analysis of a uniform core sampling pattern that yields data on tumor volume limits in negative biopsiesThe future perspectives in transrectal prostate ultrasound guided biopsyUrine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.Investigating the ability of multiparametric MRI to exclude significant prostate cancer prior to transperineal biopsy.Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.Effect of the number of biopsy cores on prostate cancer detection and staging.Imaging in prostate cancer diagnosis: present role and future perspectives.Value of multiparametric MRI in the work-up of prostate cancer.Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC map: a prospective large-scale cohort studyProstate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study.Random biopsy: when, how many and where to take the cores?Prostate cancer prediction using the random forest algorithm that takes into account transrectal ultrasound findings, age, and serum levels of prostate-specific antigen.Conditional probability of reclassification in an active surveillance program for prostate cancerMechanism underlying the negative effect of prostate volume on the outcome of extensive transperineal ultrasound-guided template prostate biopsy.Influence of serum prostate-specific antigen (PSA) level, prostate volume, and PSA density on prostate cancer detection with contrast-enhanced sonography using contrast-tuned imaging technology.
P2860
Q26795515-70A89A25-2137-4E91-B132-A5B71FF77DCCQ33610910-21BB6469-396C-4A6D-9EB4-03828D906F21Q34864858-97567359-2C3C-47D4-9FF6-BA7B90E99E54Q35632848-1A6AF5D5-1EB9-4BE9-B2F2-FEC23B6F32D6Q35678391-7E7B6E1B-8204-44DA-BBA9-99B23CC60A41Q36449937-D745261A-4260-49EA-B5A2-B1AE55FB1F2CQ37697778-7D144B48-703B-42ED-80D8-6EC84ACA4045Q37707378-E9DC3CC1-8C28-44C8-9AC3-83DD5DE8BC24Q37849513-DAFD0A71-4F34-4C59-95E5-DE318AEFF9ECQ37964563-9C1D698F-7427-4379-8A5F-F6E65217FF50Q37975995-86FE6B3F-3A27-4D95-918A-3341F63AA5B4Q38211619-D77DC235-1628-46B8-A477-58C8491AA04CQ38218443-B1318E89-D645-4AB5-8DA0-8D61316BF0FDQ39431092-A4FD16E8-F125-4F1E-8492-75B6BCD58038Q41495208-E0130C7B-AAAC-460D-AF17-31C03E3EC795Q48227944-0C6459EE-7FAA-430D-B1EF-C4FFD03AB94EQ51039277-4A3DB8B7-4244-4D04-8EE5-9A9035A257E8
P2860
Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Saturation biopsies on autopsi ...... haracterizing prostate cancer.
@en
Saturation biopsies on autopsi ...... haracterizing prostate cancer.
@nl
type
label
Saturation biopsies on autopsi ...... haracterizing prostate cancer.
@en
Saturation biopsies on autopsi ...... haracterizing prostate cancer.
@nl
prefLabel
Saturation biopsies on autopsi ...... haracterizing prostate cancer.
@en
Saturation biopsies on autopsi ...... haracterizing prostate cancer.
@nl
P2093
P2860
P1433
P1476
Saturation biopsies on autopsi ...... haracterizing prostate cancer.
@en
P2093
Gabriel P Haas
Gustavo de la Roza
Mary Jumbelic
Nicolas B Delongchamps
Richard Jones
P2860
P356
10.1111/J.1464-410X.2008.07900.X
P577
2008-08-01T00:00:00Z